Question-and-Answer Session
Operator
(Operator Instructions). Our first question comes from the line of Mark Monane with Needham & Company. Please go ahead.
Mark Monane – Needham & Company
Good morning and thank you for taking my questions. Regards from New York City.
Paul Berns
Hi Mark.
Mark Monane – Needham & Company
A couple of questions. First, let’s start with a more concrete one. In the six trials, could you update us a little bit about the NHL trial that's ongoing now, I believe, with gemcitabine and as well, could you talk about the NHL trial that is ongoing, I guess, in B-cell versus T-cell lymphoma?
Paul Berns
Sure Mark. I will have Pablo speak to that.
Pablo Cagnoni
Good morning, Mark. The trial in combination with gemcitabine is a Phase I study and we are trying refine the dose and schedule for these two agents in combination. All I can say at this point is going well. We've had a lot of interest from sites in participating and we are moving aggressively to try to find the right dose and schedule approach range and combination.
The only thing I want to say in terms of efficacy, we’ve seen some interesting results in some very heavily pre-treated patients including B-cell lymphoma patients even though it’s a Phase I study this means some very interesting evidence of activity. In terms of the Phase I /2b cell trial that’s been conducted a single institution that’s Columbia and the Principal Investigator is Owen O’Connor, and what we are doing in that study is testing the higher dose and the every other week schedule that we are using in solid tumors in patients with B-cell lymphoma and Hodgkin’s disease. So far we have five patients or so enrolled, it’s going well. There has been some early evidence that this dose might be more effective in this population that under lower dose, but that’s how we can say at this point.
Paul Berns
Mark, we are very pleased. Thank you, Pablo. We are very pleased with the activities – early activities we have seen to-date. To the Pablo’s point, the investigators are driving the recruitment of the studies and have a great level of interest in evaluating the potential clinical utility of PDX and the B-cell setting. And, as we mentioned in our prior comments, we do look forward to providing an update later in the year on those programs. I think it will be an exciting opportunity for us.
- To read the full transcript on Seeking Alpha, click here »
